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Abstract We previously observed that a creatinine
clearance (CrCl) of <65 ml/min is a signiﬁcant and
independent risk factor for the number of fallers and
falls in a community-dwelling elderly population and
postulated that this increased risk is due to the associ-
ated signiﬁcant lower D-hormone serum levels. To test
our hypothesis, we investigated in a post hoc analysis of
a double-blind randomized study whether treatment
with alfacalcidol, a synthetic prodrug of the D-hor-
mone, can reduce the high incidence of fallers and the
high risk of falls associated with low CrCl. Of 378 Swiss
community-dwelling women (n=191) and men
(n=187), aged 70 years and older, 191 received ran-
domly 1 lg capsules of alfacalcidol (AlphaD3: Teva),
and 187 received one capsule of placebo daily. With the
help of questionnaires we regularly assessed the inci-
dence and frequency of falls. The risk of becoming a
faller and the risk of falling were assessed in multivar-
iate-controlled logistic regression models according to
treatment groups and according to a CrCl cut-oﬀ of
65 ml/min. The presented results are from ITT analy-
ses. In participants with a CrCl of <65 ml/min, the 36
weeks of treatment with alfacalcidol was, compared
with placebo, associated with a signiﬁcant reduction in
the number of fallers (14/72 versus 25/70; OR 0.26,
95% CI 0.08–0.80, P=0.019), and a signiﬁcant reduc-
tion of the number of falls (16/72 versus 28/70; OR
0.29, 95% CI 0.09–0.88, P=0.028). No such association
was observed in participants with a CrCl of ‡65 ml/min
(for fallers 26/120 versus 21/116; OR 0.92 95% CI 0.34–
2.52, P=0.875; for falls 32/120 versus 23/116; OR 0.93
95% CI 0.34–2.54, P=0.885). In the placebo group
frequency of falls was dependent on CrCl (P=0.006),
whereas in the alfacalcidol treatment group frequency
of falls was independent of CrCl (P=0.494). No cases
of clinically relevant hypercalcemia were observed. In a
community-dwelling population of elderly men and
women with a CrCl of <65 ml/min, treatment with
alfacalcidol can signiﬁcantly and safely reduce the low
CrCl associated increased number of fallers and the
high risk of falls.
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Introduction
Recently published studies [1, 2] have shown that
treatment with either calcitriol in osteopenic vitamin D
replete women [1] or alfacacidiol, a synthetic D-hor-
mone pro-drug, in a population of community-dwelling
elderly vitamin D replete men and women [2] can sig-
niﬁcantly reduce the frequency of falls [1, 2] and number
of fallers [2]. This positive eﬀect of calcitriol or alfa-
calcidol on risk of falls or number of fallers is most
probably due to an increase in muscle strength [3, 4, 5]
and neuromuscular coordination [6], improved balance
[4, 5, 7] and increased functional mobility [5, 8] observed
with increasing D-hormone serum levels or under
treatment with calcitriol or alfacalcidol [7, 9].
We found that a creatinine clearance of <65 ml/min
is a signiﬁcant independent new risk factor for an
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increased frequency of falls and for becoming a faller in
a community-dwelling elderly population of men and
women. The reduced serum creatinine clearance of
<65 ml/min was signiﬁcantly associated with low
D-hormone serum concentrations, and low D-hormone
serum levels have been associated with an increased risk
of falls or risk of becoming a faller [9, 10, 11, 12]. We
therefore postulated that the low CrCl associated risk of
falls and risk of becoming a faller, which we observed in
vitamin D replete elderly men and women, is due to the
low CrCl associated low D-hormone serum levels.
Therefore, we investigated in a post-hoc analysis in this
same population of community-dwelling elderly men
and women, if treatment with alfacalcidol could reduce
the low creatinine clearance associated risk of falls and
risk of becoming a faller.
Materials and methods
This investigation was conducted as a post-hoc analy-
sis of the Swiss Aims Study [2]. The Aims study was a
large double-blind placebo-controlled randomized
study to assess the inﬂuence of a 36-week treatment
with alfacalcidol (1a-dihydroxycholcalcitriol, AlphaD3;
Teva Pharmaceutical Industries, Jerusalem, Israel), a
D-hormone pro-drug, on frequency of fallers and falls
in community-dwelling elderly men and women, 70
years old and older. The study has previously been
described in detail [2]. Of the 378 participants (191
women and 187 men), aged 70 years old and older, 191
randomly received 1 lg capsules of alfacalcidol, and
187 received one capsule of placebo daily. Falls were
assessed every 12 weeks after the baseline visit for a
total of 36 weeks. The procedure for assessment of
falls has been previously described in detail [2]. The
dietary calcium and vitamin D intake was estimated by
using a modiﬁed food frequency questionnaire [13],
which also gave information on some demographic,
lifestyle and nutritional parameters. Calcium was not
supplied, none of the participants was receiving phys-
ical therapy or training programs at study entry, and
no attempt was made to alter subjects’ diet or physical
activity during the study. In all subjects, blood samples
were drawn for measurement of serum calcium, phos-
phate, creatinine, calcidiol, D-hormone and iPTH.
Calcidiol, D-hormone and iPTH serum levels were
measured by radioimmunoassay (Nichols). In this
manuscript, we use the terminology of D-hormone for
1,25-dihydroxycalcitriol to clearly diﬀerentiate between
vitamin D and the hormonal activity of D-hormone.
The protocol of this study was approved by the Ethical
Review Board of the University of Basel, and all
participants provided written informed consent. The
Data, Safety and Monitoring Board established by
GWD Consult Germany (Safety and Monitoring
Board: GWD Consult, Research Contract, Postfach
1210, 63152 Mu¨lheim/Main, Germany), reviewed the
conduct of the study.
Statistical analyses
Comparisons of means were performed by multivariate
adjusted analyses of variance [14]. The main follow-up
multivariate analysis compared the number of fallers
and falls in the two treatment groups according to a
previously determined cut-oﬀ value for creatinine
clearance set at 65 ml/min. Those factors that reached
signiﬁcance level of P<0.1 in a screening regression
model were entered into a logistic regression model.
Multivariate diﬀerence in number of fallers and falls
between treatment groups are given as odds ratio (OR)
with 95% conﬁdence intervals (CI). According to our
previously published results [2] on the eﬀect of total
daily calcium intake on the treatment with alfacalcidol,
we also performed subgroup analyses according to cre-
atinine clearance and total daily calcium intake; even so,
our study was not designed and did not have the power
to detect signiﬁcant diﬀerences in such small subgroups.
The results presented are from multivariate-controlled
ITT analyses. A 5% signiﬁcance level was maintained
throughout these analyses, and all tests were two-sided.
The statistical analyses were conducted using the SAS
statistical software package, version 8.2, by the SAS
Institute Inc., Cary N.C., USA, licensed to the Univer-
sity of Basel, Switzerland.
Results
General
The two treatment groups were comparable at baseline.
A signiﬁcant diﬀerence was found only for the use of
phenprocoumon. Average dietary calcium intake was
generally low [mean(±SD) daily intake in mg:
512±197, respectively 521±147]. The proportion of
men to women was the same in each treatment group
and major comorbid conditions were equally distributed
between treatment groups (data not shown). Also, in
participants with a creatinine clearance of ‡65 ml/min,
the two treatment groups were comparable at baseline,
with a comparable gender distribution. A signiﬁcant
diﬀerence was found only for the use of aspirin, and
average dietary calcium intake was also generally low
(mean±SD daily intake in mg: 530±167, respectively
514±159). Comorbid conditions were equally distrib-
uted between treatment groups (data not shown).
Compared with participants with a creatinine clear-
ance of ‡65 ml/min, participants with a creatinine
clearance of <65 ml/min were multivariate controlled
signiﬁcantly older (P<0.0001), and had multivariate
controlled signiﬁcant lower BMI (P<0.0001), lower
D-hormone serum levels (P=0.010) and lower bone
density measured as T-score with ultrasound of the
calcaneus (P=0.023). Furthermore, participants with a
creatinine clearance of <65 ml/min were signiﬁcantly
more likely to be female (P=0.030) and to live alone
(P=0.042), were less likely to be diabetic (P=0.048),
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were signiﬁcantly more likely to be under a daily medi-
cation with digoxin (P=0.032), diuretics (P=0.005) and
alternative medicine (P=0.018) and were less physically
active (P=0.015) (Table 1). For all other variables we
found no signiﬁcant diﬀerences between groups
according to creatinine clearance.
Follow-up
Of the 378 participants enrolled, 321 [84.3% / 158
women (82.7%) and 163 men (87.2%)] completed the
study, with no diﬀerence in completion rate between
treatment groups (placebo 83.3% versus alfacalcidol
86.5%, P=0.649) During the study there were two
deaths, both in the group with a CrCl <65 ml/min: one
man on placebo, with long-standing heart disease, died
from myocardial infarction, and one man on alfacalcidol
after a bout of inﬂuenza died from pneumonia and
subsequent hepatitis (P=0.982, for the diﬀerence in
death rates according to treatment group).
Fallers and falls (Table 2, Fig. 1 and 2)
The multivariate analyses included predictors which
have been previously shown to be associated with
increased risk of falling, or variables which were signif-
icantly diﬀerent between treatment groups. These vari-
ables were: age, gender, body mass index (BMI),
creatinine clearance (ml/min), number of falls in previ-
ous 3 months, physical activity (sport yes/no), Charlson
comorbidity index, number of medications at baseline,
dietary calcium intake, heart rate at baseline (<80
beats/min versus ‡80 beats/min), D-hormone (pg/ml),
calcidiol (ng/ml), iPTH (pg/ml), creatinine (lmol/l) and
albumin (g/l) serum levels at baseline, changes in
D-hormone, calcidiol and iPTH serum levels over time
Table 1 Comparison of the
characteristics of the study
participants with a Creatinine
clearance of <65 ml/min vs
‡65 ml/min. BMI body mass
index, iPTH intact
parathormone, QUS
quantitative ultrasound
(calcaneus), controlled for
gender
Categories CrCl <65 ml/min
(n=142)
CrCl ‡65 ml/min
(n=236)
P-value
Gender (number), male/female 60/82 127/109 0.030
Age (mean±SD) years 76.6±4.5 74.0±3.8 <0.0001
BMI (mean±SD) kg/m2 24.6±3.0 27.5±3.9 <0.0001
Laboratory (mean±SD)
iPTH pg/ml 40.6±27.5 36.4±15.4 0.057
D-hormone pg/ml 37.6±11.9 40.7±11.2 0.010
Calcidiol ng/ml 28.5±11.8 29.8±15.8 0.422
Albumin g/l 42.5±2.8 42.1±2.9 0.150
Drug intake (in %)
Use of alternative medicine 7.2% 2.1% 0.018
Use of digoxin 4.9% 1.3% 0.032
Use of diuretics 23.3% 17.8% 0.005
Other variables (in % or mean±SD)
Living alone 38.0% 28.0% 0.042
Number of diabetics 1.4% 5.5% 0.048
History of falls in previous 3 months
before study entry
12.7% 10.7% 0.453
Regular physical activity (yes) 33.1% 45.7% 0.015
Daily dietary calcium intake (mg) 516±172 522±163 0.751
Bone density QUS (T-score) )1.08±1.58 )0.64±1.39 0.023
Timed up and go test (s) 7.0±1.8 6.9±1.7 0.518
Table 2 Eﬀect of alfacalcidol in elderly men and women on number of fallers and falls according to creatinine clearance: cut-oﬀ <65 ml/
min/‡65 ml/min
Creatinine clearance Parameter Multivariate Number of fallers/falls P-value
Adjusted OR (95% CI) Alfacalcidol vs Placebo
<65 ml/min Fallers 0.26 (0.08–0.80) 14/25 0.019a
Falls 0.29 (0.09–0.88) 16/28 0.028a
‡65 ml/min Fallers 0.92 (0.34–2.52) 26/21 0.875a
Falls 0.93 (0.34–2.54) 32/23 0.885a
aControlled for age, gender, BMI, previous falls, use of diuretics, albumin serum levels, calcidiol, D-hormone and iPTH serum levels at
baseline and during follow-up, total daily calcium intake and coﬀee consumption, use of diuretics, marcoumar, aspirin, estrogens and
multivitamins, number of co-morbidities and physical activity
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in percent, coﬀee intake, use of estrogen, phenprocou-
mon and aspirin.
In the multivariate adjusted logistic regression anal-
yses, treatment with alfacalcidol over 36 weeks was,
compared with placebo, in participants with a creatinine
clearance below 65 ml/min associated with a signiﬁcant
reduction in number of fallers (14/72 versus 25/70; OR
0.26, 95% CI 0.08–0.80, P=0.019), and a signiﬁcant
reduction in the number of falls (16/72 versus 28/70; OR
0.29, 95% CI 0.09–0.88, P=0.028) (Table 2). No such
association was observed in participants with a CrCl of
‡65 ml/min (for fallers 26/120 versus 21/116; OR 0.92
95% CI 0.34–2.52, P=0.875; for falls 32/120 versus 23/
116; OR 0.93 95% CI 0.34–2.54, P=0.885) (Table 2).
The diﬀerence in the reduction of number of fallers
and number of falls between treatment groups became
already signiﬁcant after 24 weeks of intervention for
number of fallers and for number of falls (alfacalcidol
versus placebo week 24: number of fallers 7 versus 17,
OR 0.18 95% CI 0.014–0.078, P=0.022; number of falls
9 versus 20, OR 0.22 95% CI 0.05–0.93, P=0.039)
(Fig. 1 and 2).
In subgroup analyses of participants with creatinine
clearance of <65 ml/min according to the median of
total daily calcium intake, alfacalcidol had a non-sig-
niﬁcant greater eﬀect in participants who were stratiﬁed
in the group above the median of total daily calcium
intake compared with participants stratiﬁed into the
Fig. 1 Number of fallers over
time according to treatment
groups
Fig. 2 Number of falls over
time according to treatment
groups
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group below the median daily of total daily calcium
intake (OR 0.30 95% CI 0.07–1.25 versus OR 0.66 95%
CI 0.18–2.38) (data not shown). In the alfacalcidol
treatment group, frequency of falls was independent
from CrCl (P=0.494) (data not shown).
Adverse events and side eﬀects
During the 36 weeks of intervention, we observed six
cases [one case in the placebo (CrCl ‡65 ml/min) group
and ﬁve cases in the alfacalcidol group (one with a CrCl
‡65 ml/min and four with a CrCl <65 ml/min)] of slight
transient hypercalcemia (one measurement of serum
calcium above normal with subsequent (1 week later)
control measurement within normal ranges), the highest
value measured being 2.73 mmol/l (normal range 2.10–
2.65 mmol/l). This slight transient increase in serum
calcium did not lead to a modiﬁcation of the dose of
alfacalcidol. Two participants in the alfacalcidol group,
one with a CrCl ‡65 ml/min and one with a CrCl
<65 ml/min), presented after 12 weeks of intervention
continuously till the end of the study elevated calcium
serum levels (highest value 3.00 mmol/l), without clinical
symptoms. One of these participants admitted at the end
of the study to having taken supplementary calcium
(1000 mg daily). The diﬀerence in the incidence of
hypercalcemia between study groups and according to
CrCl was not signiﬁcant (P=0.0621, respectively
P=0.260). Furthermore, we observed no diﬀerences in
the frequency of major diseases occurring during the 36
weeks between treatment groups and no cases of serious
adverse events attributable to alfacalcidol treatment.
Frequency of reported side eﬀects was equally distrib-
uted between treatment groups (82 cases in placebo
versus 75 cases in alfacalcidol, P=0.850) and indepen-
dent from creatinine clearance (P=0.878). The most
common side eﬀects were itching (placebo treatment
group: 23 cases/alfacalcidol treatment group: 22 cases)
and skin eruption (placebo treatment group: 11 cases/
alfacalcidol treatment groups 15 cases).
Discussion
We are the ﬁrst to describe a low creatinine clearance
associated risk for falls and risk of becoming a faller,
which we attributed to the signiﬁcantly lower D-hor-
mone serum levels observed with a creatinine clearance
below 65 ml/min. Therefore, we are also the ﬁrst to have
studied the eﬀect of treatment with alfacalcidol on low
creatinine clearance associated risk of falls. We observed
in community-dwelling elderly men and women that
treatment with alfacalcidol signiﬁcantly reduced the high
risk of falls and risk of becoming a faller associated with
a creatinine clearance <65 ml/min. The treatment eﬀect
of alfacalcidol on number of fallers and number of falls
already became signiﬁcant after 24 weeks of treatment
with alfacalcidol. In participants with a CrCl <65 ml/
min, alfacalcidol reduced the frequency of fallers and
falls to the frequency of fallers and falls observed in
participants with a CrCl ‡65 ml/min, for whom we
found no diﬀerence in fall and faller frequency between
treatment groups.
D-hormone has a scientiﬁcally established eﬀect on
muscle strength, balance and functional mobility [3, 4, 5,
6, 7, 8, 9], and the eﬀect of D-hormone treatment
(alfacalcidol or calcitriol) on risk of falls has been
proven in several studies [1, 2]. The low D-hormone
serum levels observed with a creatinine clearance of
<65 ml/min may also be one reason for the increased
osteopenia and osteoporosis observed with low creati-
nine clearance by other authors [15, 16]. Our result en-
hances the theory suggested by other studies [4, 5, 6, 7,
17, 18, 19, 20, 21, 22] that D-hormone is an independent
risk factor for falls [1, 2, 5, 23], and that D-hormone is
directly involved in the causal pathogenic pathway of
decreased muscle strength related falls [9, 23, 24]. It has
been recently conﬁrmed in VDR gene deleted mice that
the absence of VDR causes muscle abnormality inde-
pendently of secondary metabolic changes, e.g. hypo-
calcemia or hyperparathyroidism, and that treatment
with D-hormone counterbalances the abnormalities in
myoblastic cells and is necessary for optimal muscle
diﬀerentiation [25]. We therefore conclude that our
previously observed approximately 4 times increased
risk of falls observed in participants with a low creati-
nine clearance is due to a creatinine clearance dependent
decrease in D-hormone serum levels. Therefore treat-
ment options for patients at risk for falls should clearly
diﬀerentiate between nutritive vitamin D deﬁciency and
metabolic low D-hormone syndrome [18, 19, 20, 21].
We found an increased treatment eﬀect of alfacalc-
idol on frequency of fallers and falls in participants with
a CrCl <65 ml/min and a total daily calcium intake
above the median of 512 mg compared with participants
with a CrCl <65 ml/min and daily total calcium intake
below 512 mg. The inﬂuence of calcium intake on the
treatment eﬀect of alfacalcidol on frequency of falls and
fallers was described by us previously [2]; however, in
participants with a CrCl <65 ml/min, the inﬂuence of
calcium intake on the treatment eﬀect of alfacalcidol was
not signiﬁcant. This result may be due to the fact that
our study was not designed for power analyses in small
subgroups.
Our study has several limitations. The results come
from post hoc analyses. The participants were Caucasian
community-dwelling men and women over the age of 70
years, so our ﬁndings are not generalizable to a younger
population, institutionalized elderly or to men and
women of other races. Since our analyses were per-
formed in participants who received placebo during 36
weeks, we cannot rule out an inﬂuence in either direction
of placebo on risk of falls. Assessment of risk factors for
falls as well as the large majority of incidence of falls
during the study was based only on the participant’s
own report. Finally, we cannot exclude uncontrolled
confounding.
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In conclusion a low creatinine clearance of <65 ml/
min associated increased risk of becoming a faller and
increased risk for falls can signiﬁcantly be treated with
alfacalcidol. Our result conﬁrms our hypothesis that the
low creatinine clearance of <65 ml/min. associated risk
of becoming a faller and for falls is due to low creatinine
clearance associated low D-hormone.
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